A phase 1b randomized single-blind placebo-controlled delayed-start clinical trial of UB-312 in subjects with synucleinopathies
Brief description of study
This is a Phase 1b study to determine the safety, tolerability, and immunogenicity of UB-312 in participants with multiple system atrophy (MSA), and in participants with Parkinson’s disease (PD). UB-312 is a UBITh®-enhanced synthetic peptide-based vaccine and may provide an active immunotherapy option for treating synucleinopathies including the most prevalent form, PD; and the most rapidly progressive form, MSA.
Clinical Study Identifier: s22-00631
ClinicalTrials.gov Identifier: NCT05634876
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
